摘要
目的比较分析双时相门冬胰岛素30与预混人胰岛素30R在2型糖尿病的临床治疗效果及安全性。方法选择口服药物降糖效果差的2型糖尿病患者68例作为研究对象,随机分为双时相门冬胰岛素组34例与预混人胰岛素组34例,观察两组别的临床疗效、日均胰岛素用量及低血糖的发生率。结果双时相门冬胰岛素组、预混人胰岛素组治疗前后的FBG、2hPBG、HbA1c经t检验分析,统计学差异均有统计学意义(P<0.001);两组别间治疗后FBG、2hPBG、HbA1c经t检验分析均差异有统计学意义(P<0.05)。两组别的日均胰岛素用量、低血糖的发生次数经t检验分析,差异有统计学意义(P<0.05)。结论双时相门冬胰岛素30相对预混人胰岛素30R速效,日均胰岛素用量比较少,低血糖发生率较少,安全性高。
Objective to comparative analysis of premixed insulin aspart 30 and premixed human insulin 30R in type 2 diabetes mellitus clinical therapeutic effects and safety.Methods Selection of oral drug hypoglycemic effect was poor in patients with type 2 diabetes 68 cases as the object of study,were randomly divided into the premixed insulin aspart group 34 cases and premixed human insulin group 34 cases,observation of two groups of clinical efficacy,daily insulin dosage and the incidence of hypoglycemia.Results Premixed insulin aspart group,premixed human insulin before and after treatment,FBG,2hPBG,HbA1c by t test analysis,statistically significant difference（P0.001）,two among groups after treatment,2hPBG,FBG HbA1c by t test analysis showed statistically significant differences（P 〈0.05）.Two groups of daily insulin dosage,frequency of hypoglycemia by t test analysis,had statistical differences（P 〈0.05）.Conclusion Premixed insulin aspart 30available,short-acting relative premixed human insulin 30R in clinical treatment effect is comparatively good,daily insulin dosage is less,the rate of hypoglycemia is less,high safety,worthy of clinical application
出处
《中国实用医药》
2012年第14期10-11,共2页
China Practical Medicine
